Fig. 4: CTPI-2 influences inflammatory pathways. | Cell Death & Differentiation

Fig. 4: CTPI-2 influences inflammatory pathways.

From: Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH

Fig. 4

a Serum levels of the indicated interleukins and chemoattractant factors from mice fed the HFD and receiving vehicle (V) or CTPI-2 (T). b Quantification of liver macrophages in mice fed with control diet (C), or with the HFD and treated with vehicle (V) or CTPI-2 (T). Quantification was performed on 2–3 mice per group and from multiple fields per mouse with the ImageJ program. c Representative IHC images of F4/80 staining in the livers of the indicated treatment groups. d, e Quantification of macrophages in the WAT (d) and representative IHC images of H&E staining in the visceral adipose tissue, with crown structures indicated by arrows (e). f, g mRNA levels of the indicated genes in the livers of vehicle (black) or CTPI-2 treated mice (red). h Representative images of Picro-Sirius Red staining in the liver of the indicated mice. iNOS inducible nitric oxide synthase, TNFα tumor necrosis factor alpha, IFNγ interferon gamma, Interleukins 10–13, MRC1 Macrophage Mannose Receptor 1, FN1 fibronectin 1, Arg1 Arginase 1, Col4 Collagen 4, Col1a Collagen 1a, KRT19 Keratin 19, PDGFR platelet-derived growth factor receptor alpha, CDH1 cadherin-1. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.

Back to article page